Published online in Nature Immunology, an international research team completed a combination of blood gene expression and immune cell profiling on 178 healthy adults who had received an adjuvant vaccine for swine flu (H1N1 influenza). Approximately 20% of those vaccinated experienced an adverse response to some degree. In their findings, subtle differences were identified in early immune response, as well as the presence of a B cell-related expression signature prior and after vaccination that was associated with adverse events. Age was reviewed and determined not to be a factor creating adverse responses. Adrian Hayday , an immunobiology researcher affiliated with King's College London and the Francis Crick Institute, states that these results may contribute to understanding human immune variation and vaccine response, potentially predicting vaccine response more reliably in the future.
Quote: "We have developed new strains for IPV production with negligible risk to the human population should they escape," the researchers conclude, and add that the attributes of the new strains "allow for safe vaccine production in the post-eradication world."
It is possible that the eradication of the polio virus is near and thus, prompting discussions regarding concern for post-eradication manufacturing and stockpiling of vaccine stores containing live virus. Given the possibility of reintroduction to society through live virus escape, the World Health Organization (WHO) plans to stop the use of live-attenuated polio vaccines. WHO strongly recommends that new manufacturers to discontinue use of inactivated virus from virulent wild-type strains and to move towards an attenuated strain (Sabin). However, arguments against this have risen. Philip Minor, from the National Institute for Biological Standards and Control in Potters Bar, UK, and colleagues present data on alternative attenuated strains which they propose as a safer alternative source for inactivated vaccine. For further details, read the article published in PLOS.
Related Article: Creating safer polio vaccine strains for the post-eradication era